Skip to main content
Anteris Technologies Global Corp. logo

Anteris Technologies Global Corp. — Investor Relations & Filings

Ticker · AVR ISIN · US03675P1021 ASX Manufacturing
Open in API
Filings indexed 1,664 across all filing types
Latest filing 2019-04-09 Regulatory Filings
Country US United States of America
Listing ASX AVR

About Anteris Technologies Global Corp.

https://anteristech.com/

Anteris Technologies is a structural heart company focused on the development and commercialization of medical devices for heart valve disease. Its lead product is the DurAVR® Transcatheter Heart Valve (THV), a biomimetic valve designed for patients with severe aortic stenosis. The DurAVR® THV is engineered to mimic the performance of a healthy human aortic valve, aiming to restore normal, laminar blood flow. Clinical studies have shown the device delivers a favorable hemodynamic profile, characterized by low pressure gradients and a significant reduction in prosthesis-patient mismatch (PPM), even in patients with challenging anatomies. The company is advancing its technology through pivotal clinical trials to establish a new standard in transcatheter aortic valve replacement (TAVR) and improve long-term patient outcomes.

Recent filings

Filing Released Lang Actions
Trading Halt 2 pages 155.5KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from Admedus Limited regarding a trading halt requested by the company pending an announcement about a previously announced sale transaction and a response to a price query from the ASX. The document does not contain any financial data, report content, or detailed disclosures but is rather a notification about the trading halt status. It is short (2085 characters) and serves as an announcement rather than a report or detailed filing. Therefore, it fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2019-04-09 English
Share Sale Agreement to sell Admedus Vaccines 2 pages 103.3KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 10 April 2019 regarding a transaction update involving Admedus Ltd and its subsidiary. It details the terms of a share sale agreement, conditions precedent, and shareholder approval requirements related to the Immunotherapies Transaction. The content focuses on a corporate transaction update rather than financial results, management changes, or regulatory filings. It is not a full financial report, earnings release, or management discussion. The document is relatively short (4259 characters) and serves as an announcement of a transaction update. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2019-04-09 English
Response to ASX Price and Volume Query 5 pages 492.5KB
Regulatory Filings Classification · 95% confidence The document is a formal response from Admedus Limited to a price query issued by ASX Limited regarding unusual trading activity in the company's securities. It includes detailed answers to ASX's questions about undisclosed information, compliance with listing rules, and explanations for recent trading volume and price changes. The document is a regulatory communication addressing compliance with continuous disclosure obligations under ASX Listing Rules, specifically Listing Rule 3.1 and 3.1A. It does not contain financial statements, earnings data, or detailed financial analysis, nor is it an announcement of a report publication. Instead, it is a regulatory filing responding to a market compliance inquiry. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (9859 characters) and content confirm it is not a brief announcement but a substantive regulatory response.
2019-04-09 English
CardioCel 3D and VascuCel European regulatory approval 2 pages 125.7KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 11 March 2019 about Admedus Ltd receiving regulatory approval (CE Mark) in Europe for its CardioCel 3D and VascuCel products. It discusses the significance of the approval, product details, and future commercial plans. There are no financial statements, quarterly or annual results, or detailed financial data. The document is a corporate announcement about regulatory approval and product launch, not a financial report or earnings release. It is not a report publication announcement since it contains substantive information about the approval and company plans. Therefore, the document fits best under the category of Capital/Financing Update (CAP) as it relates to regulatory approval impacting the company's product portfolio and potential commercial expansion, which is a form of capital/strategic update. Confidence is high given the clear nature of the announcement and absence of financial data or other report types.
2019-03-10 English
Appendix 3B 9 pages 215.6KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new shares, including the class of securities, number issued, issue price, purpose, and quotation details. It references ASX rules and compliance, and includes sections on security holder approvals and quotation agreements. This type of document is a formal announcement related to new share issues and capital changes, not a full financial report or earnings release. It fits the definition of a Share Issue/Capital Change announcement, which covers new share issues and related capital structure changes.
2019-03-04 English
Appendix 4E and Preliminary Final Report 73 pages 1.8MB
Annual Report Classification · 100% confidence The document is titled 'Appendix 4E (Rule 4.3a)' and is for Admedus Limited for the financial year ended 31 December 2018. It contains detailed financial data including consolidated statements of profit or loss, financial position, cash flows, directors' report, auditor's report, corporate governance statement, and notes to the financial statements. The document includes comprehensive financial performance, operating results, capital management, and detailed management discussion. The presence of audited financial statements and the full annual period coverage indicates this is a full Annual Report. The document length is 15,000 characters, which is substantial and contains the full report, not just an announcement or summary. Therefore, the document fits the definition of an Annual Report (10-K). FY 2018
2019-02-28 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.